Novartis’ Lutathera is now the first radiopharmaceutical approved for adolescents with a rare cancer found in the gut. The ...

Pfizer and Novo Nordisk are both set to take the main stages at Cannes' advertising confab this summer. The just-announced ...

The FDA granted accelerated approval to Day One Biopharmaceuticals' pediatric brain tumor treatment. The regulator on Tuesday ...

Stephanie DeViteri is taking over as Inizio Evoke Comms’ president for North America, returning to the agency where she spent ...

China’s GNI Group announced on April 18 that it has signed an agreement with Chinese state-owned enterprises and ...

Tessera Therapeutics, Flagship’s major bet on what it calls gene writing, is letting go 13% to 14% of its workforce, a ...

Incyte said it will pay $750 million to buy San Diego biotech Escient Pharmaceuticals and its pipeline of early-stage drug ...

In the 37 years since co-founding ARCH Venture Partners, Bob Nelsen has built a reputation for placing head-turning bets on ...

Novartis appears headed in the right direction now that Sandoz has been spun out, operations have been streamlined and the ...

Endpoints News reported that former Stanford president Marc Tessier-Lavigne will lead one of biotech’s biggest-ever startup ...

To help meet the heightened demand for its injectable products, Eli Lilly is acquiring a facility from Nexus Pharmaceuticals, ...

Novartis is “actively” managing its existing relationships with Chinese service providers to mitigate risks if the Biosecure ...